Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   MANNKIND ---> Afrezza insulin BLOCKBUSTER

Amerikaanse aandelen« Terug naar discussie overzicht

MANNKIND ---> Afrezza insulin BLOCKBUSTER

Volgen
17 Posts
| Omlaag ↓
  1. MyOpinion 10 juli 2016 12:28
    INSULINE ZONDER NAALDEN VIA DE LONGEN

    https://www.youtube.com/watch?v=PefXkzTjugY

    https://www.youtube.com/watch?v=wZj4JwqJBmM

    www.youtube.com/watch?v=CbixFksNU48

    https://www.youtube.com/watch?v=jw_v7d_zoHc

    www.youtube.com/watch?v=wqU8jYpkKuM

    USERS OF AFFREZA:

    https://www.youtube.com/watch?v=yeftAVDU6kY

    www.youtube.com/watch?v=CbixFksNU48

    --------------------------------------------------

    www.google.com/finance?chdnp=0&ch...

  4. [verwijderd] 11 november 2016 11:04
    Een "Arise from the ashes" oftewel een wederopstanding...ze hebben een nieuwe overeenkomst met Sanofi getekend die goed voor hun uitpakt,

    MannKind and Sanofi Reach Agreement on AFREZZA®

    VALENCIA, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that MannKind and Sanofi have entered into an agreement with the following terms:

    The promissory note and security agreement between MannKind and Aventisub LLC, a Sanofi affiliate, are terminated, with Aventisub agreeing to forgive the full outstanding loan balance of $71.56 million.

    MannKind is also relieved from its obligation to pay $0.5 million in previously uncharged costs related to the collaboration.

    Sanofi will purchase $10.2 million worth of insulin from MannKind in early December as part of its preexisting commitment to purchase insulin following termination of the collaboration and MannKind's exercise of a "put" option.

    The balance of the insulin "put" option ($30.6 million) is accelerated with Sanofi completing the cash payment of $30.6 million to MannKind by January 9, 2017. This payment will be made without MannKind being required to deliver any insulin to Sanofi.

    All issues arising out of the license and collaboration agreement, the supply agreement, the promissory note, the security agreement and the transition agreement are resolved.

    plus on the r&d front gaan ze de strijd aan met de EPI-pen.

    komt van een 42ct naar 62ct m.i zit er nog veel meer in het vat vwb prijs..misschien wel een takeover target..
  6. [verwijderd] 13 september 2017 11:30
    9 mnd verder en nu word het tijd om ze toch maar eens goed in de gaten te houden, laatste dagen hogere volumes en hogere toppen,en denk eraan een dikke 21 milj. staat er short....btw gerucht gaat Merck zou in gesprek zijn met mnkd omtrent hun Technosphere platform,ik zeg kopen nu het nog kan want een Squeeze zit er vlgs mij aan te komen !!
  17. [verwijderd] 4 september 2018 19:17
    United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products
    September 4, 2018
    Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments
    Research agreement for additional products for additional $10 million
    SILVER SPRING, Md. and WESTLAKE VILLAGE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR)
    and MannKind Corporation (Nasdaq: MNKD) today announced that they have entered into a worldwide exclusive licensing and collaboration
    agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated
    in clinical trials for the treatment of pulmonary arterial hypertension.
    Under the agreement, United Therapeutics will be responsible for global development, regulatory and commercial activities. MannKind will
    manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Danbury, Connecticut. Long-term commercial
    supplies will be manufactured by United Therapeutics.
    Under the terms of the agreement, MannKind Corporation will receive an upfront payment of $45 million and potential milestone payments of up to $50
    million, dependent upon the achievement of specific development targets. MannKind will also be entitled to receive low double-digit royalties on net
    sales of the product. In addition, MannKind granted United Therapeutics an option to expand the license to include other active ingredients for the
    treatment of pulmonary hypertension. Each optioned product would be subject to the payment to MannKind of up to $40 million in additional option
    exercise and development milestone payments as well as a low double-digit royalty on net sales of any such product.

    deze week weer terug naar de $7,-
17 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
JUST EAT TAKEAWAY 13,590 +2,31 +20,43%
Aperam 27,680 +0,68 +2,52%
AZERION 1,248 +0,03 +2,30%
ForFarmers 3,415 +0,06 +1,94%
OCI 11,365 +0,21 +1,88%
B&S Group SA 4,320 +0,07 +1,65%
SBM Offshore 17,500 +0,25 +1,45%
Air France-KLM 7,624 +0,11 +1,44%
Basic-Fit 22,820 +0,30 +1,33%
Vopak 43,500 +0,46 +1,07%
FASTNED 21,650 +0,20 +0,93%
PROSUS 37,945 +0,34 +0,90%
ArcelorMittal 22,850 +0,19 +0,84%
TomTom 5,205 +0,04 +0,77%
AMG Critical Materials N.V. 14,530 +0,11 +0,76%
Alfen N.V. 11,890 +0,09 +0,76%
CM.COM 6,240 +0,04 +0,65%
AMX 860,98 +4,70 +0,55%
Philips Koninklijke 24,640 +0,12 +0,49%
ACOMO 17,200 +0,08 +0,47%
Vastned 24,400 +0,10 +0,41%
Sligro 11,220 +0,04 +0,36%
SHELL PLC 30,730 +0,10 +0,33%
Sif Holding 12,480 +0,04 +0,32%
KPN 3,553 +0,01 +0,25%
NSI 19,600 +0,04 +0,20%
Flow Traders 21,160 +0,04 +0,19%
Ahold Delhaize 32,200 +0,04 +0,12%
Fugro 16,120 +0,02 +0,12%
ALLFUNDS GROUP 5,340 +0,00 +0,09%
Eurocommercial Properties 23,250 0,00 0,00%
Nedap N.V. 53,800 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO (RIGHT) 0,546 -0,13 -19,78%
Kendrion 11,000 -0,34 -3,00%
IMCD 144,650 -2,75 -1,87%
NX FILTRATION 4,700 -0,09 -1,78%
INPOST 16,580 -0,29 -1,72%
EBUSCO HOLDING 1,570 -0,03 -1,72%
BESI 112,350 -1,80 -1,58%
BAM 4,108 -0,06 -1,34%
Wolters Kluwer 157,650 -2,10 -1,31%
AALBERTS NV 34,640 -0,46 -1,31%
THEON INTERNAT 8,770 -0,11 -1,24%
DSM FIRMENICH AG 101,700 -1,15 -1,12%
ASMI 518,200 -5,80 -1,11%
Galapagos 25,620 -0,26 -1,00%
ABN AMRO BANK N.V. 15,000 -0,15 -0,96%
RELX 43,420 -0,40 -0,91%
ASML 625,400 -4,90 -0,78%
Heineken 71,420 -0,54 -0,75%
PostNL 0,994 -0,01 -0,70%
Arcadis 64,550 -0,45 -0,69%
Accsys 0,580 0,00 -0,68%
ADYEN NV 1.260,600 -8,20 -0,65%
Corbion 22,240 -0,14 -0,63%
TKH 32,640 -0,20 -0,61%
Brunel 8,550 -0,05 -0,58%
Akzo Nobel 56,060 -0,32 -0,57%
RANDSTAD NV 41,230 -0,23 -0,55%
CTP 14,740 -0,08 -0,54%
ING 14,766 -0,08 -0,54%
JDE PEET'S 18,600 -0,09 -0,48%
Aegon 6,020 -0,03 -0,46%
AEX 861,42 -3,77 -0,44%
Wereldhave 13,900 -0,06 -0,43%
UMG 22,970 -0,09 -0,39%
HEIJMANS KON 25,750 -0,10 -0,39%
EXOR NV 92,750 -0,30 -0,32%
ASCX 1.178,96 -3,75 -0,32%
WDP 20,620 -0,06 -0,29%
Pharming 0,723 0,00 -0,28%
ASR Nederland 43,660 -0,12 -0,27%
Van Lanschot Kempen NV 43,250 -0,10 -0,23%
UNILEVER PLC 54,080 -0,12 -0,22%
Avantium 2,285 0,00 -0,22%
Fagron 18,780 -0,04 -0,21%
SIGNIFY NV 21,240 -0,04 -0,19%
NN Group 44,770 -0,07 -0,16%
RENEWI 6,990 -0,01 -0,14%
vlag naam koers verschil relatief verschil
AEX 861,42 -3,77 -0,44%
AEX GR 3.374,22 -13,90 -0,41%
Germany40^ 19.075,90 +42,26 +0,22%
FTSE 100 8.034,93 +9,16 +0,11%
EURO50 4.747,14 -1,60 -0,03%
US30^ 43.888,60 -43,20 -0,10%
Nasd100^ 21.059,00 -20,20 -0,10%
US500^ 5.979,16 -7,25 -0,12%
Japan225^ 38.855,90 -398,00 -1,01%
VD-NEW 16,69 +1,20 +7,74%
#/^ Index indications calculated real time, zie disclaimer